Novavax, Inc. (NVAX) and Xcellerex Collaborate on Manufacturing Process for H1N1 Flu Vaccine
Novavax Inc. and Xcellerex Inc. announced today they have entered into a strategic collaboration to accelerate the development of Novavax's vaccine manufacturing process to commercial scale. The companies will begin immediate production of Novavex's novel 2009 H1N1 influenza vaccine for potential commercial sale. Xcellerex will provide their development expertise and product manufacturing in exchange for manufacturing supply fees from Novavax. The two companies will utilize Novavax's unique virus-like particle (VLP) vaccine technology to produce initial commercial quantities of H1N1 vaccine. VLPs mimic the external structure of viruses but lack the live genetic material that causes viral replication and infection. VLPs…